In the international RUSH2A study of Jacque Duncan, MD, of the University of California, San Francisco, 70 patient spread over 9 different clinics are monitored for 4 years. In this study only syndromic and non-syndromic patients with mutations in the USH 2A gene are included.
The RUSH study – Rate of progression of USHer syndrome – was started late 2017 and takes place at about 20 clinical locations throughout the world, including the Radboudumc in Nijmegen, the Netherlands.
RUSH 2A researchers make use of various technologies to follow the changes and deterioration in eyesight and the retina.
This study is financed by the Foundation Fighting Blindness.